Mechanisms mediating bactericidal properties and conditions that enhance the potency of a broad-spectrum oligo-acyl-lysyl

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 688-695

  Sarig, Hadar ^a   Goldfeder, Yair ^a   Rotem, Shahar ^a   Mor, Amram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OLIGO ACYL LYSYL; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENVIRONMENTAL TEMPERATURE; IN VIVO STUDY; IONIC STRENGTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERMEABILITY BARRIER; PH; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HYDROGEN-ION CONCENTRATION; KINETICS; LYSINE; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE;

EID: 78751694108     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00666-10     Document Type: Article

References (66)

1. Bals, R., et al. 1998. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Invest. 102:874-880.
2. Bessalle, R., A. Kapitkovsky, A. Gorea, I. Shalit, and M. Fridkin. 1990. All-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett. 274:151-155. (Pubitemid 20378143)
3. Blondelle, S., and K. Lohner. 2000. Combinatorial libraries: a tool to design antimicrobial and antifungal peptide analogues having lytic specificities for structure-activity relationship studies. Biopolymers 55:74-87.
4. Bonnet, M., M. M. Rafi, M. L. Chikindas, and T. J. Montville. 2006. Bioenergetic mechanism for nisin resistance, induced by the acid tolerance response of Listeria monocytogenes. Appl. Environ. Microbiol. 72:2556-2563.
5. Bradshaw, J. 2003. Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs 17:233-240. (Pubitemid 36999949)
6. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250.
7. Cotter, P. D., C. Hill, and R. P. Ross. 2005. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3:777-788.
8. Dartois, V., et al. 2005. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 49:3302.
9. Deslouches, B., et al. 2005. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob. Agents Chemother. 49:3208.
10. Donnelly, J., L. Bellm, J. Epstein, S. Sonis, and R. Symonds. 2003. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect. Dis. 3:405-412.
11. Easton, D., A. Nijnik, M. Mayer, and R. Hancock. 2009. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 27:582-590.
12. Eichler, J., and R. Houghten. 1995. Generation and utilization of synthetic combinatorial libraries. Mol. Med. Today 1:174-180.
13. Epand, R., et al. 2003. Direct comparison of membrane interactions of model peptides composed of only Leu and Lys residues. Biopolymers 71:2-16.
14. Epand, R. F., et al. 2008. Dual mechanism of bacterial lethality for a cationic sequence-random copolymer that mimics host-defense antimicrobial peptides. J. Mol. Biol. 379:38-50.
15. Epand, R. F., H. Sarig, A. Mor, and R. M. Epand. 2009. Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl. Biophys. J. 97:2250-2257.
16. Fields, G. B., and R. L. Noble. 1990. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Peptide Protein Res. 35:161-214.
17. Galvez, A., H. Abriouel, R. L. Lopez, and N. Ben Omar. 2007. Bacteriocin-based strategies for food biopreservation. Int. J. Food Microbiol. 120:51-70.
18. Gandhi, M., and M. L. Chikindas. 2007. Listeria: a food-borne pathogen that knows how to survive. Int. J. Food Microbiol. 113:1-15.
19. Ganz, T. 1999. Defensins and host defense. Science 286:420-421.
20. Ge, Y., et al. 1999. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43:782-788.
21. Goldfeder, Y., F. Zaknoon, and A. Mor. Experimental conditions that enhance potency of an antibacterial oligo-acyl-lysyl. Antimicrob. Agents Chemother. 54:2590-2595.
22. Goldman, M. J., et al. 1997. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-560.
23. Gordon, Y., E. Romanowski, and A. McDermott. 2005. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30:505-515.
24. Gould, G. W. 2000. Preservation: past, present, and future. Br. Med. Bull. 56:84-96.
25. Guarna, M. M., R. Coulson, and E. Rubinchik. 2006. Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris. FEMS Microbiol. Lett. 257:1-6.
26. Hamon, M., H. Bierne, and P. Cossart. 2006. Listeria monocytogenes: a multifaceted model. Nat. Rev. Microbiol. 4:423-434.
27. Jenssen, H., P. Hammill, and R. E. W. Hancock. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19:491-511.
28. Jing, W., H. Hunter, J. Hagel, and H. Vogel. 2003. The structure of the antimicrobial peptide Ac-RRWWRF-NH2 bound to micelles and its interactions with phospholipid bilayers. J. Peptide Res. 61:219-229. (Pubitemid 36570796)
29. Lai, X. Z., et al. 2008. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc. Chem. Res. 41:1233-1240.
30. Latham, P. W. 1999. Therapeutic peptides revisited. Nat. Biotechnol. 17:755-757.
31. Lee, I. H., Y. Cho, and R. I. Lehrer. 1997. Effects of pH and salinity on the antimicrobial properties of clavanins. Infect. Immun. 65:2898-2903.
32. Lipsky, B., K. Holroyd, and M. Zasloff. 2008. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47:1537-1545.
33. Livne, L., et al. 2009. Design and characterization of a broad-spectrum bactericidal acyl-lysyl oligomer. Chem. Biol. 16:1250-1258.
34. Marr, A. K., W. J. Gooderham, and R. E. Hancock. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6:468-472.
35. Marynka, K., S. Rotem, I. Portnaya, U. Cogan, and A. Mor. 2007. In vitro discriminative antipseudomonal properties resulting from acyl substitution of N-terminal sequence of dermaseptin s4 derivatives. Chem. Biol. 14:75-85.
36. McInturff, J. E., et al. 2005. Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against Propionibacterium acnes. J. Invest. Dermatol. 125:256-263.
37. Minahk, C. J., and R. D. Morero. 2003. Inhibition of enterocin CRL35 antibiotic activity by mono- and divalent ions. Lett. Appl. Microbiol. 37:374-379.
38. Mor, A. 2009. Multifunctional host defense peptides: antiparasitic activities. FEBS J. 276:6474-6482.
39. Nicolas, P. 2009. Multifunctional host defense peptides: intracellular-targeting antimicrobial peptides. FEBS J. 276:6483-6496.
40. Oh, J. E., S. Y. Hong, and K. H. Lee. 1999. Design, synthesis and characterization of antimicrobial pseudopeptides corresponding to membrane-active peptide. J. Peptide Res. 54:129-136.
41. Perron, G. G., M. Zasloff, and G. Bell. 2006. Experimental evolution of resistance to an antimicrobial peptide. Proc. R. Soc. Lond. B Biol. Sci. 273:251-256.
42. Podda, E., et al. 2006. Dual mode of action of Bac7, a proline-rich antibacterial peptide. Biochim. Biophys. Acta 1760:1732-1740.
43. Radzishevsky, I. S., et al. 2008. Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem. Biol. 15:354-362.
44. Radzishevsky, I. S., et al. 2007. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 25:657-659.
45. Radzishevsky, I. S., et al. 2005. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob. Agents Chemother. 49:2412-2420.
46. Richard, H., and J. W. Foster. 2004. Escherichia coli glutamate- and argininedependent acid resistance systems increase internal pH and reverse transmembrane potential. J. Bacteriol. 186:6032-6041.
47. Rotem, S., and A. Mor. 2009. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788:1582-1592.
48. Rotem, S., et al. 2008. Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J. 22:2652-2661.
49. Rozek, A., J. P. Powers, C. L. Friedrich, and R. E. Hancock. 2003. Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 42:14130-14138.
50. Rulis, A. M. 2009. Agency response letter. GRAS notice no. GRN 000065. Food and Drug Administration, Washington, DC.
51. Rydlo, T., J. Miltz, and A. Mor. 2006. Eukaryotic antimicrobial peptides: promises and premises in food safety. J. Food Sci. 71:125.
52. Rydlo, T., S. Rotem, and A. Mor. 2006. Antibacterial properties of dermaseptin S4 derivatives under extreme incubation conditions. Antimicrob. Agents Chemother. 50:490-497.
53. Sarig, H., et al. 2010. A miniature mimic of host defense peptides with systemic antibacterial efficacy. FASEB J. [Epub ahead of print.]
54. Sarig, H., S. Rotem, L. Ziserman, D. Danino, and A. Mor. 2008. Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob. Agents Chemother. 52:4308-4314.
55. Shai, Y. 2002. Mode of action of membrane active antimicrobial peptides. Biopolymers 66:236-248.
56. Shai, Y., and Z. Oren. 1996. Diastereomers of cytolysins, a novel class of potent antibacterial peptides. J. Biol. Chem. 271:7305.
57. Som, A., S. Vemparala, I. Ivanov, and G. N. Tew. 2008. Synthetic mimics of antimicrobial peptides. Biopolymers 90:83-93.
58. Tew, G. N., R. W. Scott, M. L. Klein, and W. F. Degrado. 2010. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc. Chem. Res. 43:30-39.
59. Tossi, A., L. Sandri, and A. Giangaspero. 2000. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55:4-30.
60. Tossi, A., C. Tarantino, and D. Romeo. 1997. Design of synthetic antimicrobial peptides based on sequence analogy and amphipathicity. Eur. J. Biochem. 250:549-558.
61. Vaara, M. 2009. New approaches in peptide antibiotics. Curr. Opin. Pharmacol. 9:571-576.
62. Wade, D., et al. 1990. All-D-amino acid-containing channel-forming antibiotic peptides. Proc. Natl. Acad. Sci. U. S. A. 87:4761-4765.
63. Yaron, S., T. Rydlo, D. Shachar, and A. Mor. 2003. Activity of dermaseptin K4-S4 against food-borne pathogens. Peptides 24:1815-1821.
64. Yeaman, M. R., and N. Y. Yount. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55:27-55.
65. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395.
66. Zhang, L., P. Dhillon, H. Yan, S. Farmer, and R. E. Hancock. 2000. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3317-3321.